Press Releases

 
Press Releases
  Date Title and Summary View
Jul 20, 2016
AMES, Iowa, July 20, 2016 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK), today reported that it will release its second quarter 2016 financial results on Friday, July 29, 2016. The company has scheduled a conference call for 8:30 AM ET the same day to discuss the results and to give an update on clinical and business development ...
Jul 7, 2016
AMES, Iowa, July 07, 2016 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) today announced that it will participate in Cantor Fitzgerald's 2nd Annual Healthcare Conference in New York. The presentation is at 9:30 a.m. ET on Tuesday, July 12, 2016. A live webcast of the presentation will be available on the Company's website at...
Jun 6, 2016
AMES, Iowa, June 06, 2016 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK), a biopharmaceutical company focused on bringing novel immuno-oncology medicines to patients, yesterday presented data from two studies on two posters highlighting the combination therapeutic potential of indoximod, an indoleamine-(2,3)-dioxygenase (IDO) path...
Jun 3, 2016
AMES, Iowa, June 03, 2016 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) today announced that it will present two posters highlighting the indoleamine 2,3-dioxygenase pathway (IDO) inhibitor indoximod, at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting on June 5 in Chicago. The company's two abstracts at ...
Jun 2, 2016
AMES, Iowa, June 02, 2016 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) today announced that it will participate in the Jefferies 2016 Healthcare Conference in New York. The presentation is at 1:30 p.m. ET on Wednesday, June 8, 2016. A live webcast of the presentation will be available on the Company's website at www.newlin...
Jun 1, 2016
AMES, Iowa, June 01, 2016 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) today announced that Thomas P. Monath M.D., Chief Science Officer and Chief Operating Officer for the Infectious Disease Division of NewLink Genetics, will present at a scientific conference focused on the Zika virus hosted by the American Society for Microbi...
May 9, 2016
Management to Host Conference Call Tuesday, May 10th at 8:30 a.m. ET AMES, Iowa, May 09, 2016 (GLOBE NEWSWIRE) --  NewLink Genetics Corporation (NASDAQ:NLNK) announced today results of its Phase 3 clinical trial for algenpantucel-L for patients with resected pancreatic cancer.  The IMPRESS Phase 3 study of algenpantucel-L for patients with...
May 6, 2016
AMES, Iowa, May 06, 2016 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK), a biopharmaceutical company at the forefront of discovering, developing and commercializing novel immuno-oncology product candidates, including both cellular immunotherapy and checkpoint inhibitor programs, to improve the lives of patients with cancer, today ...
Apr 29, 2016
IMPRESS Phase 3 Top-line Results Now Expected in Second Quarter of 2016Pancreatic and Melanoma IDO Pathway Inhibitor Trial Updates at ASCO -Management to Host Conference Call Today at 8:30 a.m. ET AMES, Iowa and AUSTIN, Texas, April 29, 2016 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK), a biopharmaceutical company at the f...
Apr 25, 2016
AMES, Iowa, April 25, 2016 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK), a biopharmaceutical company at the forefront of discovering, developing and commercializing novel immuno-oncology and infectious disease product candidates, announced today that the Biomedical Advanced Research and Development Authority (BARDA) of the Unite...
Page: FirstPrevious
3
... NextLast
= add release to Briefcase